VIVUS, Inc. News Releases http://ir.vivus.com/ VIVUS, Inc. News Releases en VIVUS Partners with HarborPath Direct to Facilitate Access to PANCREAZE® for Patients Without Health Insurance http://ir.vivus.com/news-releases/news-release-details/vivus-partners-harborpath-direct-facilitate-access-pancreazer CAMPBELL, Calif. and CHARLOTTE, N.C., May 15, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, and HarborPath Direct, Inc. , today announced a partnership to facilitate access to PANCREAZE ® (pancrelipase) Delayed Release Capsules for uninsured or Wed, 15 May 2019 07:53:00 -0400 VIVUS, Inc. News Releases 19716 VIVUS Reports First Quarter 2019 Financial Results http://ir.vivus.com/news-releases/news-release-details/vivus-reports-first-quarter-2019-financial-results Company to host conference call today at 4:30pm ET CAMPBELL, Calif. , April 30, 2019 (GLOBE NEWSWIRE) -- VIVUS , Inc. (NASDAQ: VVUS) (the "Company"), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients Tue, 30 Apr 2019 16:05:00 -0400 VIVUS, Inc. News Releases 19676 VIVUS to Host First Quarter Business Update and Financial Results Conference Call on Tuesday, April 30, 2019 http://ir.vivus.com/news-releases/news-release-details/vivus-host-first-quarter-business-update-and-financial-results-0 CAMPBELL, Calif. , April 16, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the first quarter of 2019 after the market close on Tuesday, April 30, 2019 . The company will host a conference call beginning at Tue, 16 Apr 2019 07:30:00 -0400 VIVUS, Inc. News Releases 19656 VIVUS Announces Marketing Approval of Avanafil in the Russian Federation for the Treatment of Erectile Dysfunction http://ir.vivus.com/news-releases/news-release-details/vivus-announces-marketing-approval-avanafil-russian-federation March 14, 2019 (ACCESSWIRE via COMTEX) -- CAMPBELL, CA / ACCESSWIRE / March 14, 2019 / VIVUS, Inc. VVUS, -1.41% a biopharmaceutical company, today announced that the Ministry of Health of the Russian Federation has approved 50 mg, 100 mg and 200 mg tablets of avanafil for the treatment of erectile Thu, 14 Mar 2019 07:37:00 -0400 VIVUS, Inc. News Releases 19636 VIVUS Reports Fourth Quarter 2018 Financial Results http://ir.vivus.com/news-releases/news-release-details/vivus-reports-fourth-quarter-2018-financial-results Company to host conference call today at 4:30pm ET CAMPBELL, Calif. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- VIVUS , Inc. (NASDAQ: VVUS) (the "Company"), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with Tue, 26 Feb 2019 16:05:00 -0500 VIVUS, Inc. News Releases 19606 VIVUS to Host Fourth Quarter and Full Year Business Update and Financial Results Conference Call on Tuesday, February 26, 2019 http://ir.vivus.com/news-releases/news-release-details/vivus-host-fourth-quarter-and-full-year-business-update-and CAMPBELL, Calif. , Feb. 13, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the fourth quarter and full year of 2018 after the market close on Tuesday, February 26, 2019 . Wed, 13 Feb 2019 07:30:00 -0500 VIVUS, Inc. News Releases 19591 VIVUS Announces Date of 2019 Annual Meeting http://ir.vivus.com/news-releases/news-release-details/vivus-announces-date-2019-annual-meeting CAMPBELL, Calif. , Feb. 04, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that the Company will hold its 2019 Annual Meeting of Stockholders (the “2019 Annual Meeting”) on June 5, 2019 . Mon, 04 Feb 2019 16:00:00 -0500 VIVUS, Inc. News Releases 19576 Data Supporting the Cardiovascular Safety of VIVUS’ Qsymia® Published in The Journal of Clinical Endocrinology & Metabolism http://ir.vivus.com/news-releases/news-release-details/data-supporting-cardiovascular-safety-vivus-qsymiar-published -Study finds no increase in risk for major adverse cardiovascular events for individuals currently using phentermine in combination with topiramate; study adds to robust data supporting the safety and efficacy of Qsymia- CAMPBELL, Calif. , Jan. 14, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. Mon, 14 Jan 2019 07:30:00 -0500 VIVUS, Inc. News Releases 19521 VIVUS to Present at Biotech Showcase on January 9, 2019 http://ir.vivus.com/news-releases/news-release-details/vivus-present-biotech-showcase-january-9-2019 CAMPBELL, Calif. , Dec. 27, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today announced that Thu, 27 Dec 2018 07:30:00 -0500 VIVUS, Inc. News Releases 19506 VIVUS Reports Third Quarter 2018 Financial Results http://ir.vivus.com/news-releases/news-release-details/vivus-reports-third-quarter-2018-financial-results Company to host conference call today at 4:30pm ET CAMPBELL, Calif. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- VIVUS , Inc. (NASDAQ: VVUS) (the "Company"), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with Thu, 01 Nov 2018 16:10:00 -0400 VIVUS, Inc. News Releases 19451